Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer. Therapeutic Advances in Medical Oncology. 2023; 15. doi:10.1177/17588359231178125.

In the original published version of this paper, Figure 3 incorrectly depicted the inclusion criteria for the monarchE trial with respect to patients with Stage III N1 disease. Figure 3 has now been updated to accurately depict the inclusion of patients with Stage III N1 disease in the monarchE trial.